Financial Performance Analysis And Promotion Strategy Of Yong'an Pharmaceutical

With the improvement of social consumption level and the strengthening of people's awareness of health,China's pharmaceutical manufacturing industry has developed rapidly.However,due to its high barriers to entry and strong monopoly power,China's pharmaceutical manufacturing industry relies mainly on price means and largely ignores non-price means such as technological innovation and product research and development.Moreover,after Changchun Immortal Vaccine Time in 2018,the State Drug Administration has implemented a series of policies to regulate the pharmaceutical industry,such as market access policy,new drug approval policy,centralized drug procurement policy,drug regulatory policy,drug price management policy and pharmaceutical science and technology policy.The introduction of these policies indicates that the state will regulate and rectify the pharmaceutical market through macro-control measures to create a market environment of integrity and fair competition.This is disadvantageous to some companies that rely on price war to gain market share.They must seek a breakthrough in order to gain a foothold in the market,and improving their financial performance has undoubtedly become their lifeline.This article is divided into five parts.The first part mainly introduces the research background,research significance and research methods of the thesis,and through reading domestic and foreign literatures,studies and analyzes the relevant theories and applications of financial performance at home and abroad,and constructs the full-text analysis framework.The second part mainly expounds the meaning of performance and the concept of corporate performance evaluation,introduces four main methods of financial performance analysis,and summarizes the advantages of factor analysis in corporate financial performance analysis by comparing with traditional analysis methods to lay a solid theoretical foundation.The third part gives an overview of Yongan Pharmaceutical Company's general situation and financial situation.It elaborates the company's solvency,profitability,operation ability,development ability and shareholders' profitability,and preliminarily judges the company's financial performance.The fourth part refers to authoritative database data and index data to screen and summarize an index system suitable for factor analysis of pharmaceutical manufacturing industry.The factor analysis method is used to make a horizontal comparison of Yong 'an Pharmaceutical Industry,and the trend analysis method is used to make a vertical analysis of Yong 'an Pharmaceutical Industry.The analysis conclusion is that Yong 'an Pharmaceutical Industry has done a better job in terms of profitability and operation ability,and its debt paying ability and development ability are average.There are problems in terms of asset realization ability,rationality of capital structure,profitability of shareholders and product management.The fifth part puts forward some suggestions on the above-mentioned existing problems from the following aspects: increasing the proportion of cash assets reasonably,increasing the size of the company with appropriate debts,combining profit distribution with actual profit situation,diversified operation,multi-industry layout,etc.,hoping to provide some reference and enlightenment for the evaluation and improvement of the financial performance level of Chinese pharmaceutical manufacturing companies.